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Introduction: Atrial ﬁbrillation (AF) is the most frequent clinically signiﬁcant arrhythmia,
especially common in the elderly. As it is known, AF is associated with increased risk of
stroke. Little is known about pharmacological cardiovascular prevention in the elderly with
AF in Poland.
Objectives: The purpose of the study was to evaluate the frequency of pharmacological
stroke prevention among the elderly with AF in Poland and its association with clinical
characteristics and concomitant cardiovascular risk factors.
Patients and methods: The analysis included elderly (≥65 years) participants of the PolSenior
study performed in years 2008–2012.
Results: The study group consisted of 4979 people (mean age: 79.3  8.7 years). Among them,
there were 875 patients (18.7%) with documented history of AF. Pharmacological prevention
with the use of vitamin K antagonists (VKA) was applied by 117 (13.4%) of the elderly with AF,
including 15 (1.7%) on dual therapy. Additionally, 386 (45.3%) subjects with AF were using
oral antiplatelet therapy (OAPs), mostly aspirin. Acenocoumarol was much more often used
than warfarin. New oral anticoagulant drugs (NOACs) were not used at all. Only personal
income was associated with the use of VKA. No signiﬁcant correlation was found for the age,
sex, place of residence and level of education.
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Conclusions: The study was unique to determine the frequency of pharmacological stroke
prevention among elderly people with AF in Poland. It occurred that oral anticoagulant drugs
were applied too rarely in this group of patients. Educational programs should be developed
among general practitioners concerning current recommendations for patients with AF.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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OAPs (n = 396) Acetylsalicylic acid 387 (44.2%)
Clopidogrel 22 (2.5%)
Ticlopidine 21 (2.4%)
VKAs (n = 117) Acenocoumarol 112 (12.8)
Warfarin 13 (1.5%)
OAPs – oral antiplatelet drugs, VKAs – vitamin K antagonists.1. Introduction
Atrial ﬁbrillation (AF) is the most common clinically signiﬁcant
arrhythmia and one of the most important cardiovascular risk
factors, especially in the elderly [1]. According to the latest
studies the prevalence of AF in the general population of most
European countries is about 2% [2–4] and – as it was shown in
some meta-analyses – it doubled in the last decade [5]. The
prevalence of AF increases with aging. In subjects younger
than 49 years it is present in 0.12–0.16%, in those aged 60–70
years – in 3.7–4.2%, and in people aged 80 or older in 10–17% [5–
8]. As it was described in our previous paper, AF was present in
almost 20% of Polish people aged 65 years or older [9].
As it is well known, AF is associated with increased risk of
stroke [5,10,11]. It is estimated that AF is responsible for about
20% of strokes (so called cardiogenic strokes) [12]. According to
the latest guidelines [13–16] in all subjects with AF oral
anticoagulant drugs should be considered using CHA2DS2VASc
or – or less recommended – CHADS2 score [17].
Little is known about pharmacological cardiovascular
prevention in the elderly with atrial ﬁbrillation in Poland.
Therefore, the purpose of the study was to evaluate the
frequency of use of cardiovascular pharmacological preven-
tive therapy among the elderly with AF in Poland and its
association with clinical characteristics and concomitant
cardiovascular risk factors.
2. Patients and methods
The study was based on the data collected during the
implementation of a multicenter, publicly funded research
project commissioned by the Polish Ministry of Science and
Higher Education called ‘‘Medical, psychological, sociological
and economic aspects of aging of people in Poland (PolSenior)’’
(PBZ-MEiN-9/2/2006). A detailed description of the project has
been previously published [9]. The project was carried out from
October 2008 to April 2012. It was approved by the Bioethics
Commission.
The study group included respondents from the PolSenior
project aged 65 years and older with documented history of
atrial ﬁbrillation (AF).
The following data from the general PolSenior database
were used and analyzed: age, sex, place of residence (rural or
urban), level of education, personal income, a history of other
cardiovascular risk factors, BMI. The frequency of use of drugs
was based on the data collected in the medical part of the
questionnaire.
Statistical data analysis was performed using SAS version
9.2 (SAS Institute Inc., Gary, NC). The level of statisticalsigniﬁcance was P < 0.05. The following tests were used: the
chi-square test, Fischer's exact test, the Shapiro–Wilk test, the
Student's t-test, the Wilcoxon rank sum test, and a model of
logistic regression. The CHADS2 score was calculated accord-
ing to the general rules [17].
3. Results
The PolSenior study group consisted of 4979 people (mean age:
79.4  8.7 years). Among them, there were 875 patients (18.7%)
with documented history of AF.
There were 455 women (52.0%) and 420 men (48.0%). The
mean age of the examined subjects was 78.7  8.0 years,
similar for women and men (78.3  8.0 vs. 79.1  8.0 years,
respectively, P = 0.12).
Among all the examined subjects with AF, 498 subjects
(56.9%) used at least one drug in pharmacological prevention
of thromboembolic complications of AF. In turn, OAPs were
regularly used by 396 subjects (45.3%), whereas vitamin K
antagonists (VKAs) by 117 subjects (13.4%). One OAP was used
by 362 AF subjects (41.4%), two different OAPs by 34 (3.9%). On
the other hand, one VKA was used by 109 (12.5%) and two VKAs
by 8 subjects (0.9%). Additionally, 15 persons (1.7%) simulta-
neously used OAP and VCA (Table 1). New oral anticoagulants
(NOACs) were not used at all.
The CHADS2 score was calculated in 679 people (lack of full
required subset of data in 196 cases). Treatment with OAPs or
VKAs according to the CHADS2 score is presented in Table 2.
The percentage of women using OAPs and/or VKAs (57.9%;
n = 243) was similar as the corresponding percentage of men
(n = 255; 56.0%; P = 0.59).
Also the mean age (78.7  7.7 years) of respondents taking
VKAs and/or OAPs was similar to the mean age (78.8  8.5
years) of those with AF not treated with these drugs (P = 0.89).
Table 2 – Management of AF in people with calculated








OAPs 7 (21.2%) 47 (34.1%) 254 (50%)
VKAs – 14 (10.1%) 76 (15%)
OAPs – oral antiplatelet drugs, VKAs – vitamin K antagonists.
Table 5 – Frequency of other cardiovascular risk factors in
PolSenior study participants with atrial fibrillation
(N = 875).
Risk factor n (%) ND (n)
Previous stroke 105 (12.6%) 4
Pharmacologically treated hypertension 718 (82.1%) –




Congestive heart failure 265 (31.8%) 41
Pharmacologically treated diabetes mellitus 203 (23.3%) 5
Pharmacologically treated dyslipidemia 308 (35.2%) –
Current smoker 59 (6.8%) 2
Overweight/obesity (BMI ≥ 25 kg/m2) 627 (76.7%) 57
BMI – body mass index, ND – not documented.
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difference was found between urban (n = 327; 56.4%) and rural
areas residents (n = 170; 57.8%) (P = 0.68) concerning pharma-
cological prevention of stroke in AF. Also no signiﬁcant
differences were observed between different regions of Poland
(data not shown).
No correlation was found between the frequency of use of
OAPs and/or VKAs in subjects with AF and the level of
education (Table 3).
Personal income had a signiﬁcant effect on the frequency of
use of VKAs (P < 0.01), but not OAPs (Table 3). Only 10.8% of
participants with the lowest personal income (less than 1000
Polish zloty per month) used VKAs in comparison with 25.9%
of those with the highest income (2001 and more Polish zloty
per month) (Table 4).
The frequency of other cardiovascular risk factors in the
study group is presented in Table 5. The association between
the use of OAPs and/or VKAs in AF subjects and the presence or
the absence of other cardiovascular risk factors is presented in
Table 6.
The logistic regression analysis was made to ﬁnd which
other risk factor was mostly associated with preventive
therapy. Among all of the cardiovascular risk factors,Table 4 – Association between personal income and OAPs and
Personal income zloty/mouth n OA
Less than 1000 277 
1001–1500 245 
1501–2000 114 
2001 and more 81 
P 
ND – not documented, OAP – oral antiplatelet drugs, VKA – vitamin K an
Table 3 – Pharmacological cardiovascular prevention and educ
Level of education n OAP and
n 
Incomplete elementary 89 54 (6
Complete elementary 374 213 (
Professional 112 62 (5
High school 194 106 (
University 74 46 (6
P 0.76 
ND – not documented, OAP – oral antiplatelet drugs, VKA – vitamin K anhypertension and dyslipidemia were mostly associated with
OAP treatment, and previous stroke was associated with VCA
treatment (Table 7).
4. Discussion
According to the ESC guidelines 2016 oral anticoagulation
therapy to prevent thromboembolism is recommended for all
male AF patients with score 2 or more in CHA2DS2-VASc
(female with score 3 or more) and should be considered in male
AF patients with score 1 (female with score 2). Antiplatelet
monotherapy is not recommended for stroke prevention in AF
patients, regardless of stroke risk [16,17].
All of the examined in these study patients with AF had at
least one additional risk factor – age ≥65 years (estimated
CHA2DS2-VASc was ≥1) so in all male patients and most of







156 (56.3%) 129 (46.6%) 30 (10.8%)
137 (55.9%) 101 (41.2%) 40 (16.3%)
66 (57.9%) 56 (49.1%) 12 (10.5%)
56 (69.1%) 40 (49.4%) 21 (25.9%)
0.18 0.39 <0.01
tagonists.







0.7%) 42 (47.2%) 12 (13.5%)
57.0%) 180 (48.1%) 38 (10.2%)
5.4%) 48 (42.9%) 16 (14.3%)
54.6%) 75 (38.7%) 34 (17.5%)
2.2%) 36 (48.7%) 15 (20.3%)
0.25 0.06
tagonists.
Table 7 – Association of cardiovascular risk factors with OAP and/or VKA treatment. Data are presented as OR (95%CI) and P-
value.
Risk factor OAP and/or VKA OAP VKA
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Previous stroke 2.44 (1.36–4.37) <0.01 1.18 (0.72–1.95) 0.51 2.34 (1.28–4.28) 0.01
Pharmacologically treated hypertension 3.64 (2.33–5.69) <0.01 2.65 (1.68–4.18) <0.01 3.60 (1.4–9.28) 0.01
Previous myocardial infarct 1.07 (0.71–1.60) 0.75 1.45 (1.00–2.10) 0.05 0.77 (0.45–1.31) 0.33
Coronary heart disease (without myocardial infarct) 1.37 (0.96–1.94) 0.08 1.39 (1.00–1.93) 0.05 1.17 (0.73–1.85) 0.52
Congestive heart failure 1.63 (1.14–2.35) 0.01 1.06 (0.76–1.49) 0.73 1.89 (1.20–3.00) 0.01
Pharmacologically treated diabetes mellitus 0.91 (0.62–1.33) 0.61 1.00 (0.69–1.43) 0.98 0.66 (0.38–1.15) 0.14
Pharmacologically treated dyslipidemia 2.88 (2.02–4.11) <0.01 2.04 (1.47–2.81) <0.01 1.82 (1.16–2.85) 0.01
Current smoker 1.18 (0.63–2.21) 0.62 1.14 (0.63–2.07) 0.66 0.83 (0.33–2.10) 0.69
Overweight/obesity (BMI ≥ 25 kg/m2) 0.83 (0.57–1.23) 0.35 0.61 (0.42–0.88) 0.01 2.75 (1.37–5.54) <0.01
Sex (M/F) 1.14 (0.83–1.58) 0.42 0.90 (0.66–1.23) 0.52 1.77 (1.13–2.78) 0.01
BMI – body mass index, VKA – vitamin K antagonists, F – female, M – male, OAP – oral antiplatelet drugs.
Table 6 – Frequency of use of OAP and/or VKA in association with presence (+) or absence (S) of cardiovascular risk factors.
Data presented as n (%).






Previous stroke (+) 73 (69.5%) 53 (50.5%) 21 (20.0%)
() 423 (55.2%) 341 (44.5%) 96 (12.5%)
P <0.01 0.25 0.04
Pharmacologically treated hypertension (+) 451 (62.8%) 354 (49.3%) 112 (15.6%)
() 47 (29.9%) 42 (26.8%) 5 (3.2%)
P <0.01 <0.01 <0.01
Previous myocardial infarct (+) 127 (64.5%) 110 (55.8%) 26 (13.2%)
() 351 (54.6%) 273 (42.5%) 83 (12.9%)
P 0.01 <0.01 0.92
Coronary heart disease (without myocardial infarct) (+) 196 (66.9%) 159 (54.3%) 48 (16.4%)
() 276 (51.0%) 221 (40.9%) 58 (10.7%)
P <0.01 <0.01 0.02
Congestive heart failure (+) 176 (66.4%) 131 (49.4%) 51 (19.3%)
() 296 (52.0%) 248 (43.6%) 56 (9.8%)
P <0.01 0.11 <0.01
Pharmacologically treated diabetes mellitus (+) 118 (58.1%) 94 (46.3%) 24 (11.8%)
() 380 (57.0%) 302 (45.3%) 93 (13.9%)
P 0.77 0.80 0.44
Pharmacologically treated dyslipidemia (+) 237 (77.0%) 186 (60.4%) 63 (20.5%)
() 261 (46.0%) 210 (37.0%) 54 (9.5%)
P <0.01 <0.01 0.01
Current smoker (+) 35 (59.3%) 29 (49.2%) 6 (10.2%)
() 462 (56.8%) 367 (45.1%) 110 (13.5%)
P 0.70 0.54 0.47
Overweight/obesity (BMI ≥ 25 kg/m2) (+) 369 (58.9%) 280 (44.7%) 102 (16.3%)
() 106 (55.5%) 94 (49.2%) 14 (7.3%)
P 0.41 0.27 <0.01
Sex F 255 (56.0%) 209 (45.9%) 50 (11.0%)
M 243 (57.9%) 187 (44.5%) 67 (16.0%)
P 0.59 0.68 0.03
BMI – body mass index, VKA – vitamin K antagonists, F – female, M – male, OAP – oral antiplatelet drugs, (+) – risk factor present, () – risk factor
not present.
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elderly with AF had used oral anticoagulants, slightly over 45%
– OAPs. The most popular drug used by our respondents was
ASA (44.2%). Currently, ASA is not recommended any more.Acenocoumarol was much more popular than warfarin – it
was used by 12.8% of elderly in comparison to 1.5% of warfarin
users. Such situation was probably associated with low
availability and higher price of warfarin in the period when
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 8 2 – 3 8 7386the study was conducted. NOAC were not used by the elderly
examined in PolSenior study because they were not available
in the period when the research was done (in Europe
dabigatran and rivaroxaban were registered in 2011, and
apixaban – in 2012).
It seemed that oral anticoagulants were applied too rarely
among older people with AF in Poland, both as primary or
secondary pharmacological preventive therapy – only slightly
more than 20% of elderly after stroke used VKAs. It is
comparable to the data presented by some other Polish
authors for that period; Bednarski at al. found that oral
anticoagulants were prescribed in only 39% of people with AF
at discharge from the hospital (despite high stroke risk
calculated by CHA2DS2VASc or CHADS2 scale) [18].
In the PREFER in AF registry (Prevention of thromboembolic
events – European Registry in Atrial Fibrillation) the authors
collected data from patients in seven European countries
(Austria, France, Germany, Italy, Spain, Switzerland, and the
UK) [19]. In this study 7245 patients were enrolled, in the mean
age of 71.5 + 11 years. It was conducted from January 2012 to
January 2013, so only slightly later than the PolSenior study.
But the results are completely different. Among all the PREFER
in AF subjects, 94.2% had at least 1 point in CHA2DS2VASc score
(in PolSenior study 100% – because of age). But in this European
study oral anticoagulants were used by 82.3% of all examined
people with AF and by 84% of subjects with at least 1 point in
CHA2DS2VASc (VCAs – 78%; NOACs – 6.1%). OAPs as mono-
therapy were only used by 11.3% of people. The most rarely
oral anticoagulants were used in Italy (71.%), the most often –
in France (90%).
Also other registries from period 2005–2008 in Europe
revealed that usage of oral anticoagulants in AF was much
higher in other European countries (about 70%) than in Poland
[20,21].
Recent studies showed similar trends [22,23]. Stepinska
et al. described the baseline data from the GARFIELD-AF
registry (an ongoing prospective, multicenter, international
registry of patients newly diagnosed with AF) in Europe. The
use of VKAs was generally higher in other European countries
(41.9–55.5%) than in Poland (36.9–41.7%). The patients in this
study were younger (median age 67).
The only factor associated with the frequency of use of oral
anticoagulants in subjects with AF in this study was personal
income, similarly to our previous paper, concerning general
usage of oral pharmacological stroke prevention in the whole
PolSenior population [9]. No signiﬁcant correlation was found
for the age, sex, place of residence and level of education.
Summarizing, oral anticoagulants for stroke prevention
among elderly patients were used too infrequently and aspirin
was overused in Poland in 2008–2012. It is necessary to carry
out the current research in similar population of older AF
patients.
5. Limitation of the study
Atrial ﬁbrillation, coronary heart disease and congestive heart
failure were recognized only when they were documented.
Because lack of all data to calculate CHA2DS2VASc, less
recommended CHADS2 was used. HAS-BLED scale could notbe also calculated because of the lack of required data. It is an
analysis of data from a remote period 2008–2012.
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